Serous ovarian tumors of low malignant potential (SLMP)--also called borderline tumors of the ovary--represent a heterogeneous group of ovarian epithelial neoplasms. In general, this tumor type ...

Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...

Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an ...

Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

"We ended 2024 having made tremendous progress across our pipeline programs, including FDA acceptance of our NDA with ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Avutometinib and defactinib target KRAS-mutated recurrent low-grade serous ovarian cancer, potentially becoming the first FDA-approved treatment for this specific cancer type. The NDA is supported by ...

Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...